Retatrutide Dosage Protocol (10 mg Vial)

Straightforward 12-week and 24-week planning for a 10 mg vial at 10 mg/mL.

• Retatrutide vials (10 mg each):
  • Phase 2, 12 weeks: Minimum 6 vials (56 mg required).
  • Phase 2, 24 weeks: Minimum 20 vials (200 mg required).
  • Phase 3, 12 weeks: Minimum 5 vials (48 mg required).
  • Phase 3, 24 weeks: Minimum 18 vials (180 mg required).
• U-100 insulin syringes (1 mL capacity):
  • Phase 2, 12 weeks: 12 new syringes.
  • Phase 2, 24 weeks: 36 new syringes.
  • Phase 3, 12 weeks: 12 new syringes.
  • Phase 3, 24 weeks: 32 new syringes.
• Bacteriostatic water (10 mL bottles):
  • Phase 2, 12 weeks: 1 bottle by volume (6 mL required).
  • Phase 2, 24 weeks: 2 bottles by volume (20 mL required).
  • Phase 3, 12 weeks: 1 bottle by volume (5 mL required).
  • Phase 3, 24 weeks: 2 bottles by volume (18 mL required).
• Alcohol swabs:
  • Phase 2, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 2, 24 weeks: 72 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 12 weeks: 24 swabs minimum; 1 box of 100 covers the calculation.
  • Phase 3, 24 weeks: 64 swabs minimum; 1 box of 100 covers the calculation.

Sharps disposal: One appropriately sized container for used syringes.

Stability planning: Vial and diluent totals are minimum arithmetic quantities. Follow the exact product documentation for sterility, storage, handling loss, and discard timing.

Retatrutide 10 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Reconstitute: Add 1 mL of bacteriostatic water to produce 10 mg/mL.
• Research frequency: Once weekly by subcutaneous administration in the cited human trials.^[1][3][5]
• Weekly research range: The cited programs evaluated target amounts through 12 mg weekly.^[1][2][3]
• Easy measuring: 1 U-100 unit = 0.01 mL = 100 mcg.
• Vial size: The 10 mg label is total nominal vial content, not a weekly amount. Weekly research amounts above 10 mg require enough vials to supply the total nominal mass.
• Vial coverage: At the 2 mg research stage, one vial supplies 5 full weekly amounts. At the 12 mg research stage, the 12 mg amount requires 2 separate 10 mg vials by nominal mass. These are mass calculations, not vial storage or discard periods.

The exact-strength protocol separates clinical-trial schedules from reconstitution and vial arithmetic.

• Route and frequency: Once-weekly subcutaneous administration was used in the cited phase 2 and phase 3 trials.^[1][2][3][5]
• Studied targets: Phase 2 evaluated 1 mg, 4 mg, 8 mg, and 12 mg groups. Phase 3 programs evaluated 4 mg, 9 mg, and 12 mg targets.^[1][2][3]
• Concentration: The stated 10 mg vial mass divided by 1 mL equals 10 mg/mL.
• U-100 conversion: 1 unit equals 0.01 mL or 100 mcg at this concentration.
• Evidence boundary: Trial schedules describe investigated products and populations. They are not individualized dosing instructions.^[1][3][5][6]

Phase 2 and phase 3 used related but distinct Retatrutide dose-escalation designs.

• Phase 2 lower-start 12 mg arm: 2 mg, 4 mg, 8 mg, and then 12 mg in four-week stages.^[1][10]
• Phase 3 12 mg target: 2 mg, 4 mg, 6 mg, 9 mg, and then 12 mg in four-week stages.^[2][3]
• Other target groups: The programs included lower assigned targets rather than escalating every participant to 12 mg.^[1][2][3][5]
• Measurement: The primary chart keeps weekly peptide mass, U-100 units, mL, and frequency together.
• Strength consistency: Vial strength does not change the assigned research amount. It changes vial yield and how many vials are needed.

A single vial provides different numbers of complete research amounts at each studied target.

• 2 mg: 20 units or 0.20 mL, providing 5 complete amounts per vial.
• 4 mg: 40 units or 0.40 mL, providing 2 complete amounts with 2 mg remaining.
• 6 mg: 60 units or 0.60 mL, providing 1 complete amount with 4 mg remaining.
• 9 mg: 90 units or 0.90 mL, providing 1 complete amount with 1 mg remaining.
• 12 mg: 120 units or 1.20 mL, requiring enough nominal mass from 2 separate vials. Avoid unnecessary agitation and repeated freeze-thaw cycles because peptide stability is formulation-dependent.^[16]

This vial reconstituted with 1 mL has the exact-strength concentration shown above. Each 0.01 mL U-100 unit contains 0.1 mg, or 100 mcg. The calculation keeps reconstitution volume, syringe markings, and vial yield together.

• A 2 mg research amount equals 0.20 mL or 20 U-100 units. One vial contains 5 complete amounts.
• A 4 mg amount equals 0.40 mL or 40 units. One vial contains 2 complete amounts with 2 mg remaining.
• A 6 mg amount equals 0.60 mL or 60 units. One vial contains 1 complete amount with 4 mg remaining.
• An 8 mg amount equals 0.80 mL or 80 units. One vial contains 1 complete amount with 2 mg remaining.
• A 9 mg amount equals 0.90 mL or 90 units. One vial contains 1 complete amount with 1 mg remaining.
• A 12 mg amount equals 1.20 mL or 120 units and exceeds the nominal mass in one vial. The supply calculation therefore requires 2 vials and 2 syringes for that administration. Vial-yield figures are arithmetic, not storage or discard periods.

Retatrutide dosing in the cited studies was organized around assigned target groups and gradual escalation. The trial design determines the research schedule. Vial size does not determine the weekly dose.

• The phase 2 obesity trial randomized participants to placebo or target groups of 1 mg, 4 mg, 8 mg, or 12 mg once weekly. Higher target groups used different starting and escalation approaches, including a lower 2 mg start that improved gastrointestinal tolerability compared with a 4 mg start.^[1][10]
• The phase 2 type 2 diabetes trial evaluated several assigned Retatrutide doses and an active comparator. Its population, endpoints, and schedule context differ from the obesity trial.^[5][12]
• The TRIUMPH phase 3 program used once-weekly subcutaneous administration with assigned target doses and planned four-week escalation stages.^[2]
• TRANSCEND-T2D-1 evaluated 4 mg, 9 mg, and 12 mg target doses in adults with type 2 diabetes whose glycemic control was inadequate with diet and exercise.^[3]
• The clinical-trial registry identifies the tested protocol and population. It does not validate a separately manufactured research vial or a self-directed schedule.^[6]

Retatrutide is an investigational single molecule designed to activate three metabolic hormone receptors: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon.

• GIP and GLP-1 receptor activity contributes to glucose-dependent insulin signaling, appetite regulation, and nutrient-response pathways.
• Glucagon receptor activity adds a distinct energy-expenditure and hepatic-signaling component to the research profile.
• Preclinical and translational work describes the balance of activity across the three receptors and the compound's extended pharmacokinetic profile.^[4]
• Reviews of multi-receptor agonists explain why triple agonism is being investigated for obesity and metabolic disease. Receptor activity alone does not establish a safe dose for an individual.^[7][8]

Clinical findings must be interpreted by trial, target dose, population, follow-up period, and analysis method. Results from one group should not be transferred to a different schedule or vial formulation.

• In the 48-week phase 2 obesity trial, mean body-weight change was dose-related, with the largest average reduction reported in the 12 mg target group.^[1]
• The phase 2 type 2 diabetes trial reported changes in glycated hemoglobin and body weight across the evaluated Retatrutide groups.^[5]
• TRANSCEND-T2D-1 reported phase 3 glycemic and body-weight outcomes at 40 weeks in adults with type 2 diabetes.^[3]
• Cardiometabolic measurements were assessed as secondary or exploratory outcomes and require population-specific interpretation.^[1][3][5][9]
• A phase 2a substudy evaluated liver-fat change in participants with metabolic dysfunction-associated steatotic liver disease. Those findings do not convert a research vial into a liver-treatment protocol.^[11]

Safety findings apply to the investigated products, monitored participants, and controlled escalation plans. Trial evidence, vial conversions, and informal schedules are different evidence categories.

• Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation were among the most frequently reported adverse events.^{[1][3][5][12]}
• A 2 mg starting amount improved gastrointestinal tolerability compared with a 4 mg start in the phase 2 obesity study.^[1]
• Dose-dependent heart-rate increases were observed in phase 2 and declined after peaking during follow-up.^[1]
• Trial design papers and registries describe assigned targets, eligibility criteria, comparators, and monitoring that are not reproduced by a vial calculation.^[2][6]
• Mechanistic and review literature can explain triple-receptor agonism but cannot independently validate a clinical dose.^[4][7][8]
• Cardiovascular and hepatic discussions remain outcome-specific and should not be converted into broad treatment claims.^[9][11]

How much BAC water for 10mg Retatrutide depends on the concentration selected by the governing research protocol. This reconstitution guide and calculator use the page's stated water volume to match its exact-strength math. Reconstitute Retatrutide only under documented procedures; Retatrutide is investigational.^{[6][13][14][15]}

• Water volume: Verify the intended dilution and product instructions before adding BAC water.
• Lyophilized material: If the peptide vial contains lyophilized powder, insert the needle into the Retatrutide vial at an angle and direct the liquid down the wall rather than directly onto the powder.
• Mixing: Gently swirl or roll; never shake.
• Label and storage: Record the date of reconstitution and concentration, then refrigerate only as the exact product documentation specifies.
• U-100 check: At this concentration, 10 units represents one-tenth of the syringe volume and 100 units represents the full syringe volume.
• Mistakes to avoid: Do not treat syringe units as peptide IU or change the water volume without recomputing concentration. These injection-calculation notes are for informational purposes, not individualized medical advice.^[13][14][15]

These frequently asked questions clarify how to read this strength's chart and reconstitution math without turning research data into individualized medical advice.^[13][14][15]

• What concentration results from adding the stated volume? The page uses a 10 mg/mL concentration. On a U-100 insulin syringe, 1 unit equals 0.01 mL or 100 mcg.
• Does vial size change the Retatrutide dose used in a trial? No. Strength changes reconstitution volume, yield, and supply calculations. It does not change the assigned research amount.
• How often was Retatrutide administered in the cited trials? The cited phase 2 and phase 3 studies used once-weekly subcutaneous administration.^[1][2][3][5]
• Did every participant escalate to 12 mg? No. Trials included multiple assigned target groups, and participants followed the protocol for their randomized group.^[1][2][3][5]
• Why do 12 mg rows require two vials? That amount exceeds the nominal mass in one vial. The chart therefore counts two containers, and the 1.20 mL volume requires two 1 mL U-100 syringes.
• How should research administration be documented? Follow the governing protocol, use a new sterile syringe, clean the vial stopper and selected site, rotate sites, record mass, units, mL, date, and site, and place used sharps into an appropriate container.^[13][14][15]

This page summarizes published human research schedules and the corresponding arithmetic for reconstituting this vial. It does not establish an approved product, a recommended dose, or individualized medical advice.

• 1
  New England Journal of Medicine (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity: randomized phase 2 trial

  View Source
• 2
  Diabetes, Obesity and Metabolism (2026): TRIUMPH Phase 3 trial design, target doses, and escalation

  View Source
• 3
  The Lancet (2026): TRANSCEND-T2D-1 randomized phase 3 retatrutide trial

  View Source
• 4
  Cell Metabolism (2022): Discovery and translational pharmacology of LY3437943

  View Source
• 5
  The Lancet (2023): Retatrutide for type 2 diabetes: randomized phase 2 trial

  View Source
• 6
  ClinicalTrials.gov: Phase 2 retatrutide obesity study NCT04881760

  View Source
• 7
  Current Obesity Reports (2025): Triple agonism-based therapies for obesity

  View Source
• 8
  Nature Reviews Endocrinology (2024): Multi-receptor agonists for metabolic disease

  View Source
• 9
  Diabetes Care (2024): Incretin-based therapies and cardiovascular considerations

  View Source
• 10
  New England Journal of Medicine (2023): Supplementary material for the phase 2 obesity trial

  View Source
• 11
  Nature Medicine (2024): Retatrutide for metabolic dysfunction-associated steatotic liver disease: randomized phase 2a trial

  View Source
• 12
  The Lancet (2023): Supplementary data for the phase 2 diabetes trial

  View Source
• 13
  CDC: Subcutaneous administration guidance

  View Source
• 14
  Johns Hopkins Arthritis Center: How to give a subcutaneous injection

  View Source
• 15
  NCBI Bookshelf: Best practices for injections and related procedures

  View Source
• 16
  Journal of Pharmaceutical Sciences (2018): Stability considerations during freeze-thaw cycles

  View Source

Compare the other Retatrutide vial sizes and practical measurement guides.